Candid Therapeutics Advances Portfolio of Novel T-Cell Engagers into Five Autoimmune Diseases for Clinical Evaluation
— First Patients Dosed with BCMA T-cell engager (cizutamig) and CD20 T-cell engager (CND261) — Clinical Studies in IgA Nephropathy, Myasthenia Gravis, Rheumatoid Arthritis, Systemic Lupus Erythemotosus and Systemic Sclerosis are Underway — CMC Established to Facilitate Global Clinical Trials — China Operations Established for Early Clinical Development San Diego, CA, June 20, 2025: Candid […]
